Loading...
•
Dec 31, 2024
Glaukos Q4 2024 Earnings Report
Glaukos reported strong Q4 2024 results with record net sales and improved financial performance.
Key Takeaways
Glaukos achieved record Q4 2024 net sales of $105.5 million, representing a 28% year-over-year increase. The company reported a net loss of $33.6 million, a reduction from the prior year's loss, while non-GAAP net loss improved to $22.2 million. Operating loss also narrowed, and the company ended the quarter with a strong cash position of $324 million.
Q4 2024 net sales grew 28% year-over-year to $105.5 million.
Glaucoma segment sales reached $84.1 million, up 39% year-over-year.
Net loss narrowed to $33.6 million, with non-GAAP net loss at $22.2 million.
Gross margin stood at 73%, while non-GAAP gross margin was 82%.
Glaukos
Glaukos
Glaukos Revenue by Segment
Revenue by Segment
Glaucoma Revenue
CapyFin.com Forward Guidance
Glaukos expects continued strong growth in 2025, with net sales projected between $475 million and $485 million.
Positive Outlook
- 2025 net sales guidance set between $475 million and $485 million.
- Continued strong demand for glaucoma treatment products.
- Ongoing expansion of proprietary, long-duration drug delivery technology.
- Improvement in operating efficiency and cost management.
- Solid financial position with strong cash reserves and no debt.
Challenges Ahead
- Potential impact of macroeconomic conditions on revenue growth.
- Fluctuations in foreign exchange rates affecting international sales.
- Increased costs related to R&D and commercialization efforts.
- Competitive pressures in the ophthalmic pharmaceutical market.
- Regulatory uncertainties related to new product approvals.